Earnings History Data for NovoCure Limited (NVCR) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

NovoCure Limited

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
30-10-2024	PM		NVCR	NovoCure Limited	1,800	-0.28	-0.34	-0.46	NovoCure GAAP EPS of -$0.28 beats by $0.05, revenue of $155.09M beats by $11.14M [10/30/2024 7:01 AM]	16.96	0.07 (0.44%)	16.99	0.10 (0.59%)	10.87 - 24.74	1,456,223	1,610,000	20,807
NovoCure Q3 2024 Earnings Preview [10/29/2024 11:52 AM] NovoCure GAAP EPS of -$0.28 beats by $0.05, revenue of $155.09M beats by $11.14M [10/30/2024 7:01 AM] Novocure appoints Moderna's exec Christoph Brackmann as CFO [10/30/2024 7:28 AM] Novocure Reports Third Quarter 2024 Financial Results [2024-10-30 07:00AM] NovoCure: Q3 Earnings Snapshot [2024-10-30 07:10AM] Novocure Appoints Christoph Brackmann as Chief Financial Officer [2024-10-30 07:02AM]
25-07-2024	PM		NVCR	NovoCure Limited	2,020	-0.31	-0.40	-0.54	NovoCure GAAP EPS of -$0.31 beats by $0.09, revenue of $150.4M beats by $14.57M [7/25/2024 7:01 AM]	18.62	-0.17 (-0.90%)	19.57	0.78 (4.15%)	10.87 - 41.51	1,577,795	1,040,000	6,630
NovoCure Q2 2024 Earnings Preview [7/24/2024 1:32 PM] NovoCure GAAP EPS of -$0.31 beats by $0.09, revenue of $150.4M beats by $14.57M [7/25/2024 7:01 AM]
02-05-2024	PM		NVCR	NovoCure Limited	1,370	-0.36	-0.43	-0.50	NovoCure GAAP EPS of -$0.36 beats by $0.06, revenue of $138.5M beats by $7.05M [5/2/2024 7:07 AM]	14.18	1.44 (11.30%)	13.30	0.56 (4.39%)	10.87 - 83.60	1,310,192	1,060,000	7,767
Novocure secures new $400M multi-tranche debt financing, shares up [5/2/2024 7:51 AM] NovoCure GAAP EPS of -$0.36 beats by $0.06, revenue of $138.5M beats by $7.05M [5/2/2024 7:07 AM] NovoCure Q1 2024 Earnings Preview [5/1/2024 11:42 AM]
22-02-2024	PM		NVCR	NovoCure Limited	1,720	-0.45	-0.53	-0.36	NovoCure GAAP EPS of -$0.45 beats by $0.07, revenue of $133.78M in-line [2/22/2024 7:01 AM]	15.24	-0.38 (-2.43%)	16.60	0.98 (6.27%)	10.87 - 83.60	1,111,590	1,060,000	1,124
NovoCure Q4 2023 Earnings Preview [2/21/2024 11:34 AM] NovoCure GAAP EPS of -$0.45 beats by $0.07, revenue of $133.78M in-line [2/22/2024 7:01 AM]
26-10-2023	PM		NVCR	NovoCure Limited	1,510	-0.46	-0.51	-0.25	NovoCure GAAP EPS of -$0.46 beats by $0.07, revenue of $127.32M misses by $1.44M [10/26/2023 7:10 AM]	12.99	-1.09 (-7.71%)	14.18	0.10 (0.71%)	12.64 - 120.03	1,887,629	1,190,000	1,331
NovoCure Q3 2023 Earnings Preview [10/25/2023 2:02 PM] NovoCure GAAP EPS of -$0.46 beats by $0.07, revenue of $127.32M misses by $1.44M [10/26/2023 7:10 AM]
27-07-2023	PM		NVCR	NovoCure Limited	4,070	-0.54	-0.50	-0.23	NovoCure GAAP EPS of -$0.54 misses by $0.04, revenue of $126.05M beats by $1.8M [7/27/2023 7:11 AM]	33.92	-6.42 (-15.91%)	39.38	-0.96 (-2.39%)	33.54 - 120.03	2,561,660	1,360,000	3,485
NovoCure Q2 2023 Earnings Preview [7/26/2023 12:27 PM] NovoCure GAAP EPS of -$0.54 misses by $0.04, revenue of $126.05M beats by $1.8M [7/27/2023 7:11 AM]
04-05-2023	PM	7:10 AM ET (May 4)	NVCR	NovoCure Limited	6,940	-0.50	-0.39	-0.04	NovoCure GAAP EPS of -$0.50 misses by $0.16, revenue of $122.18M misses by $5.75M [5/4/2023 7:16 AM]	66.82	0.88 (1.33%)	61.00	-4.94 (-7.49%)	56.06 - 120.03	699,470	570,000	4,326
NovoCure Q1 2023 Earnings Preview [5/3/2023 1:56 PM] NovoCure GAAP EPS of -$0.50 misses by $0.16, revenue of $122.18M misses by $5.75M [5/4/2023 7:16 AM]
23-02-2023	PM	7:10 AM ET (Feb 23)	NVCR	NovoCure Limited	8,890	-0.36	-0.32	-0.25	NovoCure GAAP EPS of -$0.36 misses by $0.07, revenue of $128.43M beats by $1.23M [2/23/2023 7:08 AM]	78.37	-3.64 (-4.44%)	80.00	-2.01 (-2.45%)	56.39 - 120.03	1,002,409	480,000	493
NovoCure Q4 2022 Earnings Preview [2/22/2023 12:27 PM] NovoCure GAAP EPS of -$0.36 misses by $0.07, revenue of $128.43M beats by $1.23M [2/23/2023 7:08 AM]
27-10-2022	PM	7:00 AM ET (Oct 27)	NVCR	NovoCure Limited	7,010	-0.25	-0.30	-0.13	NovoCure GAAP EPS of -$0.25 beats by $0.03, revenue of $130.99M misses by $2.39M [10/27/2022 7:11 AM]	67.77	0.06 (0.09%)	67.71	0.0 (0.00%)	56.39 - 116.56	658,081	580,000	7,128
NovoCure GAAP EPS of -$0.25 beats by $0.03, revenue of $130.99M misses by $2.39M [10/27/2022 7:11 AM]
28-07-2022	PM	7:00 AM ET (Jul 28)	NVCR	NovoCure Limited	7,510	-0.23	-0.14	-0.14	NovoCure GAAP EPS of -$0.23 misses by $0.09, revenue of $140.9M beats by $5.77M [7/28/2022 7:05 AM]	70.21	-3.75 (-5.07%)	72.00	-1.96 (-2.65%)	56.39 - 185.91	1,112,137	380,000	332
NovoCure Q2 2022 Earnings Preview [7/27/2022 1:16 PM] NovoCure GAAP EPS of -$0.23 misses by $0.09, revenue of $140.9M beats by $5.77M [7/28/2022 7:05 AM] Novocure stock down 10% on wider-than-expected Q2 loss [7/28/2022 11:00 AM] Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program [Jul-27-22 08:00AM] Novocure Reports Second Quarter 2022 Financial Results [Jul-28-22 07:00AM]
28-04-2022	PM	7:00 AM ET (Apr 28)	NVCR	NovoCure Limited	8,140	-0.04	-0.17	-0.04	NovoCure GAAP EPS of -$0.04 beats by $0.15, revenue of $137.55M beats by $3.26M [4/28/2022 7:06 AM]	77.22	0.27 (0.34%)	76.95	0.0 (0.00%)	59.57 - 232.76	589,148	530,000	10,602
NovoCure Q1 2022 Earnings Preview [4/27/2022 2:11 PM] NovoCure GAAP EPS of -$0.04 beats by $0.15, revenue of $137.55M beats by $3.26M [4/28/2022 7:06 AM] Novocure Reports First Quarter 2022 Financial Results [Apr-28-22 07:00AM] NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates [Apr-28-22 08:35AM] Novocure (NVCR) Q1 2022 Earnings Call Transcript [Apr-28-22 01:30PM]
24-02-2022	PM	6:30 AM ET (Feb 24)	NVCR	NovoCure Limited	8,080	-0.25	-0.10	0.04	NovoCure GAAP EPS of -$0.25 misses by $0.15, revenue of $133.21M misses by $1.28M [2/24/2022 7:07 AM]	77.04	4.08 (5.59%)	0.0	0.0 (0.00%)	59.57 - 232.76	840,755	739,083	0
NovoCure Q4 2021 Earnings Preview [2/23/2022 11:11 AM] NovoCure GAAP EPS of -$0.25 misses by $0.15, revenue of $133.21M misses by $1.28M [2/24/2022 7:07 AM] New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response [Feb-24-22 07:05AM] Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update [Feb-24-22 07:00AM] NovoCure (NVCR) Reports Q4 Loss, Lags Revenue Estimates [Feb-24-22 08:35AM] Novocure (NVCR) Q4 2021 Earnings Call Transcript [Feb-24-22 02:00PM] Novocures General Counsel Resigns After 10 Years of Service [Feb-24-22 04:24PM]
28-10-2021	PM	6:00 AM ET (Oct 28)	NVCR	NovoCure Limited	11,770	-0.13	-0.06	0.09	NovoCure EPS misses by $0.06, misses on revenue [10/28/2021 6:35 AM]	101.68	-9.10 (-8.21%)	106.00	-4.78 (-4.31%)	100.00 - 232.76	1,437,972	430,000	21,878
NovoCure Q3 2021 Earnings Preview [10/27/2021 12:45 PM] Novocure completes enrollment in late-stage TTFields ovarian cancer study [10/28/2021 6:35 AM] NovoCure EPS misses by $0.06, misses on revenue [10/28/2021 6:35 AM] NovoCure slips after Q3 miss and extended timeline for pivotal trial [10/28/2021 9:56 AM] Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update [Oct-28-21 06:30AM] Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer [Oct-28-21 06:30AM] NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates [Oct-28-21 08:55AM] NovoCure (NVCR) Q3 2021 Earnings Call Transcript [Oct-28-21 05:01PM] Why NovoCure Stock Is Sinking This Week [Oct-28-21 04:29PM]
29-07-2021	PM	6:00 AM ET (Jul 29)	NVCR	NovoCure Limited	18,650	-0.14	0.02	0.02	NovoCure EPS misses by $0.15, misses on revenue [7/29/2021 6:01 AM]	164.02	-17.90 (-9.84%)	171.00	-10.92 (-6.00%)	67.56 - 232.76	4,161,508	370,000	5,948
NovoCure Q2 2021 Earnings Preview [7/28/2021 12:45 PM] NovoCure EPS misses by $0.15, misses on revenue [7/29/2021 6:01 AM] NovoCure shares fall after Q2 earnings miss [7/29/2021 8:18 AM] Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update [Jul-29-21 06:00AM] NovoCure (NVCR) Reports Q2 Loss, Misses Revenue Estimates [Jul-29-21 07:35AM] NovoCure (NVCR) Q2 2021 Earnings Call Transcript [Jul-29-21 03:01PM] Why Novocure Tanked on Thursday [Jul-29-21 05:18PM]
29-04-2021	PM	6:00 AM ET (Apr 29)	NVCR	NovoCure Limited	22,290	-0.04	0.01	0.04	NovoCure EPS misses by $0.06, misses on revenue [4/29/2021 6:01 AM]	205.31	-0.19 (-0.09%)	205.31	0.0 (0.00%)	55.40 - 220.48	932,779	1,010,000	6,827
NovoCure Q1 2021 Earnings Preview [4/28/2021 1:06 PM] NovoCure EPS misses by $0.06, misses on revenue [4/29/2021 6:01 AM] Novocure slips 5% as Q1 earnings miss expectations [4/29/2021 9:08 AM] Why NovoCure (NVCR) Might Surprise This Earnings Season [Apr-28-21 08:47AM] NovoCure Ltd. to Host Earnings Call [Apr-29-21 05:45AM] Novocure Reports First Quarter 2021 Financial Results and Provides Company Update [Apr-29-21 06:00AM] Novocure Reports Surprise Loss As Revenue Falls Short [Apr-29-21 07:29AM] Novocure Stock Skids On Surprise Loss As Revenue Also Falls Short [Apr-29-21 09:29AM] NovoCure (NVCR) Q1 2021 Earnings Call Transcript [Apr-29-21 02:00PM]
25-02-2021	PM	6:00 AM ET (Feb 25)	NVCR	NovoCure Limited	17,610	0.04	0.13	0.04	NovoCure EPS misses by $0.09, beats on revenue [2/25/2021 6:04 AM]	148.69	-24.44 (-14.12%)	167.98	-5.15 (-2.97%)	53.40 - 194.75	1,597,493	610,189	4,866
NovoCure EPS misses by $0.09, beats on revenue [2/25/2021 6:04 AM] NovoCure Q4 2020 Earnings Preview [2/24/2021 12:17 PM] NovoCure (NVCR) Q4 2020 Earnings Call Transcript [Feb-25-21 08:01PM] Why NovoCure Stock Sank Today [Feb-25-21 03:32PM]
29-10-2020	PM	6:00 AM ET (Oct 29)	NVCR	NovoCure Limited	12,080	0.09	0.04	0.02		123.27	7.88 (6.83%)	119.99	4.60 (3.99%)	53.40 - 140.89	1,260,467	871,136	1,059

30-07-2020	PM	6:00 AM ET (Jul 30)	NVCR	NovoCure Limited	6,790	0.02	0.00	-0.01	NovoCure EPS beats by $0.02, beats on revenue [7/30/2020 6:03 AM]	74.96	6.96 (10.24%)	73.39	5.39 (7.93%)	53.40 - 98.84	1,187,674	731,894	4,934